Measuring cognitive change in Alzheimer's disease clinical drug trials.
In the following paper the cognitive measures used in clinical trials of drugs for Alzheimer's disease are reviewed. The potential benefits of employing innovative tests that map cognitive domains poorly indexed by traditional measures such as the ADAS-cog are considered. Finally, issues pertaining to the cognitive breadth of any proposed new instrument are discussed, as well as the clinical relevance of cognitive change.
Harrison
J E
JE
J.E. Harrison, 16 Haygrove Close, Warminster Wiltshire BA12 8SL, United Kingdom. john@ceepcee.com
D000368:Aged; D000544:Alzheimer Disease / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology*; D003071:Cognition / Q000187:drug effects* / Q000502:physiology; D018450:Disease Progression; D006801:Humans; D008609:Mental Status Schedule; D009483:Neuropsychological Tests; D018697:Nootropic Agents / Q000627:therapeutic use*; D012720:Severity of Illness Index; D016896:Treatment Outcome
D018697:Nootropic Agents